KLOW vs Wolverine Stack: Skin-and-Gut Healing Blend vs Pure Tissue Repair
KLOW and the Wolverine Stack both get called “healing” protocols, but they are built for different jobs. The Wolverine Stack (wolverine) is the focused injury-repair pair — BPC-157 + TB-500, nothing else. KLOW (klow) is a broader, GHK-Cu-dominant four-peptide blend built around skin regeneration and gut/inflammatory healing, that happens to include the two Wolverine peptides.
TL;DR: The Wolverine Stack (BPC-157 + TB-500) is pure tissue repair — tendon, ligament, muscle, systemic recovery — dosed as two independently controllable vials. KLOW (GHK-Cu + KPV + BPC-157 + TB-500) is a single-vial skin-and-gut healing blend with a copper-peptide backbone and anti-inflammatory KPV. Choose Wolverine for a targeted injury; choose KLOW for skin, collagen, and inflammatory/gut healing.
Research-use disclosure: For educational purposes only, not medical advice. None of these peptides is FDA-approved; all are research-use-only, and BPC-157/TB-500 are WADA-prohibited. Dosing reflects community protocols. VialBase may earn a commission on vendor links, which does not influence the content here.
At a Glance
| Property | Wolverine Stack | KLOW |
|---|---|---|
| Components | BPC-157 + TB-500 | GHK-Cu + KPV + BPC-157 + TB-500 |
| Copper peptide (GHK-Cu) | No | Yes (50 mg — the backbone) |
| Anti-inflammatory (KPV) | No | Yes (10 mg) |
| Primary goal | Tendon / ligament / muscle / systemic tissue repair | Skin regeneration, collagen, gut & inflammatory healing |
| Format | Two separate vials (dosed independently) | One pre-mixed vial (fixed ratio) |
| Local injection | Yes — BPC-157 near the injury site | No — whole blend, subcutaneous |
| Independent dose control | Yes (tune each peptide) | No (fixed blend) |
| Dosing | BPC-157 250–500 mcg 1–2x/day; TB-500 2–5 mg 2x/wk → weekly | 10–20 units SubQ daily |
| Best for | A specific injury you want to target | Broad skin + healing + anti-inflammatory coverage |
The key structural difference: Wolverine is two tools you aim precisely; KLOW is one blend that covers more ground but can’t be tuned.
What Each Is Built For
The Wolverine Stack is the community name for BPC-157 + TB-500 — the two most-studied tissue-repair peptides, run together because they are mechanistically complementary. BPC-157 concentrates local repair (and can be injected at the injury site); TB-500 drives systemic, body-wide remodeling. There is no copper peptide and no dedicated anti-inflammatory — it is a focused repair protocol. Because the two are dosed as separate vials, you can front-load TB-500 for an acute injury or inject BPC-157 locally, independently of each other. (See the BPC-157 vs TB-500 comparison for how the two differ.)
KLOW is a GHK-Cu-dominant blend. By mass it is mostly GHK-Cu (50 of ~80 mg) — the copper-peptide engine for skin, hair, collagen, and gut tight-junction support — with KPV added for anti-inflammatory coverage and BPC-157 + TB-500 rounding out the repair side. It is sold as a single pre-mixed vial, which is convenient but fixes the ratios: you take the whole blend or none of it.
The Overlap — and Why It Doesn’t Make Them Interchangeable
KLOW contains both Wolverine peptides (BPC-157 and TB-500 at 10 mg each), so there is real overlap in tissue-repair action. But two things keep them from being substitutes:
- Ratio lock. In KLOW, BPC-157 and TB-500 are fixed at 10 mg each inside a GHK-Cu-heavy blend. You cannot raise TB-500 for a weekly loading protocol or push BPC-157 without also taking more GHK-Cu and KPV. A dedicated Wolverine protocol lets you dose each to its own optimal schedule.
- Delivery. Wolverine lets you inject BPC-157 locally at an injury and dose TB-500 systemically on its own cadence. KLOW is a single whole-blend subcutaneous injection — good for broad coverage, not for targeting one structure.
So KLOW gives you some Wolverine-style repair as part of a wider skin/gut blend, while Wolverine gives you precise, tunable repair and nothing you don’t need.
Which Should You Choose?
- A specific tendon, ligament, or muscle injury → Wolverine Stack. Independent dosing plus local BPC-157 injection make it the precise tool.
- Acute injury needing a strong start → Wolverine, front-loading TB-500 (which tolerates high loading doses) alongside local BPC-157.
- Skin regeneration, collagen, hair, anti-aging → KLOW (or Glow if you don’t need KPV) — the GHK-Cu backbone is the point.
- Gut / inflammatory healing → KLOW. KPV plus GHK-Cu tight-junction support target inflammation the Wolverine pair does not.
- Broad “everything” single-vial convenience → KLOW. It covers skin, gut, inflammation, and repair in one injection, at the cost of tunability.
For full protocols with per-component unit math, see the KLOW dosage chart, the individual BPC-157 and TB-500 dosage charts, and the KLOW and Wolverine stack profiles.
Dosing
Wolverine Stack (two vials, never mixed in one syringe): BPC-157 250–500 mcg 1–2x daily, often injected subcutaneously near the injury; TB-500 2–5 mg twice weekly for 4–6 weeks (loading), then ~2 mg weekly (maintenance), injected subcutaneously anywhere.
KLOW (single vial): reconstitute with 2 mL bacteriostatic water and inject 10–20 units (0.1–0.2 mL) subcutaneously daily, starting at 10 units. Some users dose every other day to moderate TB-500 accumulation.
Frequently Asked Questions
What is the difference between KLOW and the Wolverine Stack? They target different jobs. The Wolverine Stack is BPC-157 + TB-500 — a two-peptide injury-repair pair with no copper peptide, focused on tendon, ligament, muscle, and systemic tissue recovery. KLOW is a GHK-Cu-dominant four-peptide blend (GHK-Cu + KPV + BPC-157 + TB-500) built for skin regeneration, collagen, and gut/inflammatory healing. Wolverine is pure repair; KLOW is skin-and-gut healing with repair peptides included.
Which is better for injury recovery, KLOW or Wolverine? For a specific tendon, ligament, or muscle injury, the Wolverine Stack (BPC-157 + TB-500) is the more focused choice — it delivers both repair peptides at independently controllable doses, and BPC-157 can be injected locally at the injury site. KLOW contains BPC-157 and TB-500 too, but at fixed blend ratios (10 mg each) alongside GHK-Cu and KPV, so it is less tunable for a dedicated injury protocol.
Can KLOW replace the Wolverine Stack? Partly. KLOW includes both Wolverine peptides (BPC-157 and TB-500 at 10 mg each), so it provides some of the same tissue-repair action plus copper-peptide skin work and KPV anti-inflammatory coverage. But because the ratios are fixed, you cannot independently raise TB-500 for weekly loading or inject BPC-157 locally the way a dedicated Wolverine protocol allows. For a targeted injury, Wolverine is more precise; for broad skin-plus-healing, KLOW is more complete.
Do KLOW and Wolverine use the same dosing? No. KLOW is a single pre-mixed vial dosed at 10–20 units subcutaneously daily. The Wolverine Stack is two separate vials — BPC-157 (250–500 mcg 1–2x daily, often injected near the injury) and TB-500 (2–5 mg loading twice weekly, then weekly) — which are never mixed in the same syringe. Wolverine gives independent control of each peptide; KLOW trades that for single-vial convenience.
Are KLOW and the Wolverine Stack FDA-approved? No. Every peptide in both is research-use-only in the US, none is on the 503A bulks list, and BPC-157 and TB-500 are WADA-prohibited. Community dosing guides are a starting point, not medical advice. Avoid with active cancer or during pregnancy.